China regulator mulls cutting traditional medicine prices: report

China regulator mulls cutting traditional medicine prices: report

6:17am EST

HONG KONG (Reuters) – Chinese regulators are considering cutting retail price limits on some traditional Chinese medicines (TCM) by as much as 10 percent early next year, a newspaper controlled by the official Xinhua news agency reported. This follows a regulatory crackdown on real or perceived corporate wrongdoing this year, with domestic and international manufacturers of infant formula and drugs coming under the spotlight. The Economic Information Daily, citing unidentified sources, reported on Thursday that the National Development and Reform Commission (NDRC) was looking to reduce prices of top-end, non-essential products, which had risen sharply due to supportive policies. Beijing Tongrentang and Shijiazhuang Yiling Pharmaceutical are among the firms that will be most affected, given the range of such medicines that they offer, the report said. The agency expects to see prices for a small number of such products drop by up to 25 percent in two years, according to the report. Traditional Chinese medicine products classified as “essential” by the NDRC and those identified as state secrets will be exempted from this ruling.

About bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (, the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: